Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Brief Summary: This is a Phase IIIb multicenter study to evaluate the safety and efficacy of certolizumab pegol (CZP) administered to patients with moderate-to-severe rheumatoid arthritis.


Options:
A: Arm Label: Phase 1 Etanercept + methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Phase 1: Etanercept, Drug: Phase 1: Methotrexate, Drug: Phase 2: Optional ETN, SSZ, HCQ, MTX | Arm Label: Phase 1 Conventional DMARD (SSZ or HCQ) + MTX; Type: ACTIVE_COMPARATOR; Interventions: Drug: Phase 1: Methotrexate, Drug: Phase 1: Conventiaonal DMARD | Intervention Type: BIOLOGICAL; Name: Phase 1: Etanercept; Assigned to Arm(s): Phase 1 Etanercept + methotrexate | Intervention Type: DRUG; Name: Phase 1: Methotrexate; Assigned to Arm(s): Phase 1 Etanercept + methotrexate | Intervention Type: DRUG; Name: Phase 2: Optional ETN, SSZ, HCQ, MTX; Assigned to Arm(s): Phase 1 Etanercept + methotrexate | Intervention Type: DRUG; Name: Phase 1: Methotrexate; Assigned to Arm(s): Phase 1 Conventional DMARD (SSZ or HCQ) + MTX | Intervention Type: DRUG; Name: Phase 1: Conventiaonal DMARD; Assigned to Arm(s): Phase 1 Conventional DMARD (SSZ or HCQ) + MTX
B: Arm Label: Certolizumab pegol (CZP); Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol (CZP) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol (CZP); Assigned to Arm(s): Certolizumab pegol (CZP) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: ADA+MTX/PBO+MTX (Arm 1); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate, Biological: placebo | Arm Label: ADA+MTX/ADA+MTX (Arm2); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate | Arm Label: ADA+MTX/OL ADA+MTX (Arm 3); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate | Arm Label: PBO+MTX/PBO+MTX (Arm 4); Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Biological: placebo | Arm Label: PBO+MTX/OL ADA+MTX (Arm 5); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate, Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): ADA+MTX/ADA+MTX (Arm2), ADA+MTX/OL ADA+MTX (Arm 3), ADA+MTX/PBO+MTX (Arm 1), PBO+MTX/OL ADA+MTX (Arm 5) | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): ADA+MTX/ADA+MTX (Arm2), ADA+MTX/OL ADA+MTX (Arm 3), ADA+MTX/PBO+MTX (Arm 1), PBO+MTX/OL ADA+MTX (Arm 5), PBO+MTX/PBO+MTX (Arm 4) | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): ADA+MTX/PBO+MTX (Arm 1), PBO+MTX/OL ADA+MTX (Arm 5), PBO+MTX/PBO+MTX (Arm 4)
D: Arm Label: 5mg; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 | Arm Label: 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biologic TNFi | Intervention Type: DRUG; Name: CP 690,550; Assigned to Arm(s): 5mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 10 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2 | Intervention Type: BIOLOGICAL; Name: Biologic TNFi; Assigned to Arm(s): adalimumab

Answer: B